Cellectis (LSE:0WA2) - Stock Price, News & Analysis

0WA2 Stock Overview

Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells.

About the company

0WA2 fundamental analysis
Snowflake Score
Valuation	3/6
Future Growth	2/6
Past Performance	0/6
Financial Health	5/6
Dividends	0/6

Rewards

Revenue is forecast to grow 38.15% per year

Trading at good value compared to peers and industry

Risk Analysis

Currently unprofitable and not forecast to become profitable over the next 3 years

Shareholders have been diluted in the past year

Cellectis S.A. Competitors

Oxford Biomedica

LSE:OXB

UK£220.0m

Bioventix

AIM:BVXP

UK£231.0m

NIOX Group

AIM:NIOX

UK£286.6m

Arecor Therapeutics

AIM:AREC

UK£41.8m

Price History & Performance

Summary of all time highs, changes and price drops for Cellectis
Historical stock prices
Current Share Price	€2.37
52 Week High	€3.43
52 Week Low	€0.92
Beta	3.13
1 Month Change	2.67%
3 Month Change	-10.66%
1 Year Change	32.00%
3 Year Change	-85.00%
5 Year Change	-86.65%
Change since IPO	-90.66%

Recent updates

Shareholder Returns

	0WA2	GB Biotechs	GB Market
7D	0.1%	-0.4%	2.2%
1Y	32.0%	-29.1%	0.9%

Return vs Industry: 0WA2 exceeded the UK Biotechs industry which returned -29.5% over the past year.

Return vs Market: 0WA2 exceeded the UK Market which returned 0.6% over the past year.

Price Volatility

Is 0WA2's price volatile compared to industry and market?
0WA2 volatility
0WA2 Average Weekly Movement	6.7%
Biotechs Industry Average Movement	6.8%
Market Average Movement	4.8%
10% most volatile stocks in GB Market	11.3%
10% least volatile stocks in GB Market	2.7%

Stable Share Price: 0WA2 has not had significant price volatility in the past 3 months.

Volatility Over Time: 0WA2's weekly volatility has decreased from 26% to 7% over the past year.

About the Company

Founded	Employees	CEO	Website
1999	234	Andre Choulika	www.cellectis.com

Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma. It also develops UCART22 to treat B-cell acute lymphoblastic leukemia; UCARTCS1 and ALLO-605 for the treatment of multiple myeloma; ALLO-316 for renal cell carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART 20x22 for relapsed or refractory B-Cell NHL.

Cellectis S.A. Fundamentals Summary

How do Cellectis's earnings and revenue compare to its market cap?
0WA2 fundamental statistics
Market cap	€170.77m
Earnings (TTM)	-€67.01m
Revenue (TTM)	€22.86m

7.5x

P/S Ratio

-2.5x

P/E Ratio

Is 0WA2 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
0WA2 income statement (TTM)
Revenue	US$24.53m
Cost of Revenue	US$1.26m
Gross Profit	US$23.26m
Other Expenses	US$95.15m
Earnings	-US$71.89m

Last Reported Earnings

Sep 30, 2023

Next Earnings Date

May 09, 2024

Earnings per share (EPS)	-1.00
Gross Margin	94.86%
Net Profit Margin	-293.13%
Debt/Equity Ratio	41.4%

How did 0WA2 perform over the long term?

See historical performance and comparison

0WA2 Stock Overview

Rewards

Risk Analysis

Cellectis S.A. Competitors

LSE:OXB

UK£220.0m

AIM:BVXP

UK£231.0m

AIM:NIOX

UK£286.6m

AIM:AREC

UK£41.8m

Price History & Performance

Recent News & Updates

Cellectis Presents Novel TALEN® Editing Processes Enabling Highly Efficient Gene Correction and Gene Insertion in HSPCs

Cellectis S.A. Announces Board Appointments

New major risk - Shareholder dilution

New minor risk - Profitability

Third quarter 2023 earnings released: US$0.31 loss per share (vs US$0.63 loss in 3Q 2022)

New major risk - Revenue and earnings growth

Recent updates

Cellectis Presents Novel TALEN® Editing Processes Enabling Highly Efficient Gene Correction and Gene Insertion in HSPCs

Cellectis S.A. Announces Board Appointments

New major risk - Shareholder dilution

New minor risk - Profitability

Third quarter 2023 earnings released: US$0.31 loss per share (vs US$0.63 loss in 3Q 2022)

New major risk - Revenue and earnings growth

Cellectis S.A. to Report Q3, 2023 Results on Nov 06, 2023

Less than half of directors are independent

Cellectis and Imagine Institute Publish A Proof-Of-Concept Study of A Gene Surgery Candidate to Treat Activated Phosphoinositide 3-Kinase ? Syndrome Type 1 (APDS1)

Second quarter 2023 earnings released: US$0.089 loss per share (vs US$0.42 loss in 2Q 2022)

Cellectis S.A. to Report Q2, 2023 Results on Aug 03, 2023

New minor risk - Share price stability

Cibus Global, Ltd. completed the acquisition of Calyxt, Inc. (NasdaqCM:CLXT) from Cellectis S.A. (ENXTPA:ALCLS) and others in a reverse merger transaction.

Cellectis S.A., Annual General Meeting, Jun 27, 2023

Cellectis S.A. Presents Clinical Data on AMELI-01 and Preclinical Data on Multiplex Engineering for Superior Generation of CAR T- Cells at ASGCT 2023

Cellectis Publishes Article in Frontiers in Immunology Unveiling Pre-Clinical Data on A Novel Treatment Paradigm for Successful Car T Immunotherapy Against Stroma-Rich Solid Tumors

Cellectis Announces Poster Presentation on BALLI-01 at the European Hematology Association (EHA) 2023

No longer forecast to breakeven

Now 21% undervalued after recent price drop

Cellectis S.A. has completed a Follow-on Equity Offering in the amount of $22 million.

Cellectis S.A. has completed a Follow-on Equity Offering in the amount of $22 million.

Cellectis S.A. announced that it has received $20 million in funding from Cytovia Therapeutics, Inc.

Cellectis S.A. announced that it has received $20 million in funding from Cytovia Therapeutics, Inc.

Cibus Global, Ltd. entered into a definitive merger agreement to acquire Calyxt, Inc. (NasdaqCM:CLXT) from Cellectis S.A. (ENXTPA:ALCLS) and others in a reverse merger transaction.

Cibus Global, Ltd. entered into a definitive merger agreement to acquire Calyxt, Inc. (NasdaqCM:CLXT) from Cellectis S.A. (ENXTPA:ALCLS) and others in a reverse merger transaction.

Insufficient new directors

Cellectis S.A. Announces the Resignation of Alain Godard as a Member of the Board

Cellectis Announces First Dosing of a Patient with its In-house Manufactured Product Candidate UCART22 for the treatment of r/r B-cell ALL

Cellectis S.A Announces Positive Preliminary Clinical Data for UCART22 in ALL and UCART123 in AML

Third quarter 2022 earnings released: US$0.63 loss per share (vs US$0.82 loss in 3Q 2021)

Cellectis to Showcase Clinical Data from Ameli-01 and Preclinical Data from Ucartcs1 At Ash 2022

Cellectis S.A. to Report Q3, 2022 Results on Nov 03, 2022

Cellectis Presents Data on Two TALEN®-based Gene Therapy Preclinical Programs for Patients with Sickle Cell Disease and Mucopolysaccharidosis type I at ESGCT 2022

Cellectis Appoints Mark Frattini as Chief Medical Officer

Second quarter 2022 earnings released: US$0.42 loss per share (vs US$0.88 loss in 2Q 2021)

Cellectis S.A. Announces Executive Changes

Cellectis S.A. Announces U.S. Food and Drug Administration Clear Cellectis’ Investigational New Drug Application to Initiate A Phase 1/2A Clinical Trial of UCART20x22 for Patients

Cellectis S.A. to Report Q2, 2022 Results on Aug 04, 2022

Cellectis Announces the Appointment of Axel-Sven Malkomes & Dr. Donald A Bergstrom, M.D., Ph.D., to its Board of Directors

Cellectis S.A., Annual General Meeting, Jun 28, 2022

Cellectis Presents Research Data on A Novel Immune-Evasive Universal CAR T-Cell At ASGCT

First quarter 2022 earnings released: US$0.70 loss per share (vs US$0.28 loss in 1Q 2021)

Cellectis S.A. to Report Q1, 2022 Results on May 12, 2022

Cellectis S.A. Releases Preclinical Data on Its Product Candidate UCART20x22 At the American Association for Cancer Research Annual Meeting

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Cellectis S.A. to Report Q4, 2021 Results on Mar 03, 2022

Cellectis Appoints Bing C. Wang as Member of its Executive Committee

Cellectis’ Licensed Partner, Allogene Therapeutics, Announces Removal of FDA Clinical Hold on their Clinical Trials

Cellectis Reports Encouraging Clinical Data from BALLI-01 Study in Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia, and Preclinical Data from TALGlobin01 at the 63rd American Society of Hematology Annual Meeting

Senior Vice President of Technical Operations - Europe Leopold Bertea has left the company

Third quarter 2021 earnings released: US$0.82 loss per share (vs US$0.71 loss in 3Q 2020)

Second quarter 2021 earnings released: US$0.88 loss per share (vs US$0.76 loss in 2Q 2020)

Cellectis S.A. Announces New Product Candidate Pipeline, and Manufacturing and Technologies

First quarter 2021 earnings released: US$0.28 loss per share (vs US$0.47 profit in 1Q 2020)

Cellectis S.A. Announces Preliminary Results from its Phase 1 Balli-01 Clinical Study of Ucart22 in Adults with R/R B-All Presented in Oral Session At 2020 Ash Annual Meeting

Full year 2020 earnings released: US$1.91 loss per share (vs US$2.41 loss in FY 2019)

Revenue beats expectations

Cellectis S.A. to Report Q4, 2020 Results on Mar 04, 2021

New 90-day low: €18.11